MedTrace Logo

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

NCT04088864 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-03-30

No results posted yet for this study

Summary

The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and lymphoma). Another purpose of this study is to test the safety and cancer killing ability of a cell therapy against a new cancer target (CD22).

Conditions

  • B Cell Lymphoma
  • Acute Lymphoblastic Leukemia, Pediatric
  • Lymphoma

Interventions

DRUG

Fludarabine

Fludarabine is a purine antagonist antimetabolite

DRUG

Cyclophosphamide

Cyclophosphamide is a nitrogen mustard derivative alkylating agent

DRUG

Autologous CD22 CAR T

Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)

Sponsors & Collaborators

Principal Investigators

  • Liora Schultz, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-10
Primary Completion
2023-10-31
Completion
2036-09-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04088864 on ClinicalTrials.gov